Richter transformation in the era of novel agents

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents. Here, I review the contemporary literature on Richter transformation, particularly in the context of novel agents used in CLL, and discuss the management approach for these patients.

Original languageEnglish (US)
Pages (from-to)256-263
Number of pages8
JournalHematology. American Society of Hematology. Education Program
Volume2018
Issue number1
DOIs
StatePublished - Nov 30 2018

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Lymphoma, Large B-Cell, Diffuse
Non-Hodgkin's Lymphoma
Lymphoma
Drug Therapy
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Richter transformation in the era of novel agents. / Ding, Wei D.

In: Hematology. American Society of Hematology. Education Program, Vol. 2018, No. 1, 30.11.2018, p. 256-263.

Research output: Contribution to journalReview article

@article{ef7ca4f2e58e4c4dbd2ec65bd974e3f8,
title = "Richter transformation in the era of novel agents",
abstract = "Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4{\%} to 20{\%} of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents. Here, I review the contemporary literature on Richter transformation, particularly in the context of novel agents used in CLL, and discuss the management approach for these patients.",
author = "Ding, {Wei D}",
year = "2018",
month = "11",
day = "30",
doi = "10.1182/asheducation-2018.1.256",
language = "English (US)",
volume = "2018",
pages = "256--263",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Richter transformation in the era of novel agents

AU - Ding, Wei D

PY - 2018/11/30

Y1 - 2018/11/30

N2 - Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents. Here, I review the contemporary literature on Richter transformation, particularly in the context of novel agents used in CLL, and discuss the management approach for these patients.

AB - Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents. Here, I review the contemporary literature on Richter transformation, particularly in the context of novel agents used in CLL, and discuss the management approach for these patients.

UR - http://www.scopus.com/inward/record.url?scp=85058770743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058770743&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2018.1.256

DO - 10.1182/asheducation-2018.1.256

M3 - Review article

VL - 2018

SP - 256

EP - 263

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

IS - 1

ER -